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Introduction: Infection with high-risk types of human papillomavirus 
(hrHPV) is associated with cervical, anogenital, and oropharyngeal 
cancers. Since a causal contribution of hrHPV infection to lung cancer 
(LC) is still a matter of debate, a comprehensive study was performed 
to delineate hrHPV involvement in LC, using a Dutch study population.
Methods: Archival tissue specimens from 223 patients (145 men, 78 
women, median age 65 years, range 27–87 years), who presented with 
cancer in the lungs, were subjected to GP5+/6+ polymerase chain 
reaction and p16INK4A immunohistochemistry. The series included pri-
mary lung carcinomas of patients without a history of cancer (n = 175), 
primary lung carcinomas of patients with an unrelated cancer in the 
past (n = 36), and carcinomas with primary presentation in the lungs 
of which the origin (i.e., primary or metastasis) was equivocal at 
the time of diagnosis (n = 12). GP5+/6+ polymerase chain reaction/
p16INK4A double-positive carcinomas were subjected to HPV geno-
typing, HPVE7 transcript analysis, loss of heterozygosity analysis, 
and array-comparative genomic hybridization.
Results: Whereas all primary lung carcinomas were hrHPV-negative 
(211 of 211, 100%), three hrHPV–positive equivocal carcinomas (3 
of 12, 25%) were identified. These patients (1 male, 2 females) had 
a history of hrHPV-associated disease; one tonsillar and two cervi-
cal carcinomas. A clonal relationship between individual tumor pairs 
was supported by identical hrHPV genotype, pattern of p16INK4A 
expression, HPVE7 mRNA expression, and genomic aberrations.
Conclusions: hrHPV presence in a tumor with primary presentation 
in the lungs signifies pulmonary metastasis from a primary hrHPV–
positive cancer elsewhere in the body. No support was found for an 
attribution of hrHPV infection to the development of primary LC.
Key Words: Human papillomavirus, Non–small cell lung cancer, 
Primary cancer, Metastatic disease.
(J Thorac Oncol. 2013;8: 711–718)
Lung cancer (LC) is the leading cause of cancer-related death worldwide.1 Apart from etiological factors, such 
as tobacco smoke exposure and (occupational) exposure 
to asbestos, radon, arsenic, and outdoor air pollution,2 viral 
agents have been implicated in lung carcinogenesis.3–5 Certain 
types of human papillomavirus (HPV) are firmly established 
as human carcinogens.6 Infection with high-risk (hr) types 
of HPV has been recognized as the main causative event for 
almost all cervical carcinomas,7 a subset of other anogenital 
cancers, including vaginal, penile, vulvar, and anal cancers,8,9 
and a proportion of oropharyngeal cancers.10–12 However, the 
association and therefore a potential etiological link between 
hrHPV infection and LC remains controversial.
Many studies have reported on the prevalence of 
hrHPV in LCs with highly variable and conflicting data, 
that is, hrHPV prevalence figures ranged from 0% to 80% 
among studies and showed an average frequency of 20% 
to 25% worldwide.13–16 The discrepancies observed might 
be explained by a difference in geographical distribution of 
hrHPV prevalence and/or interlaboratory variation regarding 
sample collection and sample handling methodologies. Also, 
differences regarding the method used for hrHPV detection 
are likely to contribute to the observed heterogeneity in 
prevalence worldwide. Previous studies evaluating the role 
of HPV infections in lung carcinogenesis addressed only 
part of the criteria that were postulated to prove a causal 
involvement of HPV in carcinogenesis.17,18 In particular, the 
sole demonstration of HPV DNA present in tumor specimens 
by means of polymerase chain reaction (PCR)-based detection 
assays, as used in many studies, provides insufficient evidence 
for a causal relationship. As such, many aspects of the 
association between HPV infections and the development of 
LC remain elusive.
A widely accepted gold standard for the detection of 
a biologically relevant association between hrHPV infection 
and cancer is the measurement of viral E6/E7 oncogene tran-
scripts in tumor specimens. Expression of viral oncogenes 
E6 and E7 plays a crucial role in malignant transformation 
and maintenance of the transformed state by inactivating 
host tumor-suppressor genes p53 and pRB, respectively.19–21 
However, although measurement of viral oncogene expression 
can be reliably performed on snap-frozen samples, it is not 
readily feasible on routine formalin-fixed, paraffin–embedded 
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(FFPE) material, as mRNA isolates of FFPE sample origin 
are often of poor quality. Therefore, alternative methods have 
been proposed to assess HPV involvement using FFPE mate-
rials. A comparison of various (combinations of) methods has 
proposed p16INK4a immunohistochemistry (IHC) together with 
consensus primer hrHPV DNA PCR (i.e., GP5+/6+ PCR) to 
provide outcomes that are equivalent to transcript analysis on 
corresponding frozen samples.22 This algorithm has recently 
been validated on a series of head-and–neck squamous cell 
carcinoma FFPE specimens by showing 98% accuracy.12
The current study aimed to delineate hrHPV involve-
ment in LC, using LC specimens collected in a Dutch study 
population (n = 223), with the help of GP5+/6+ PCR together 
with p16INK4a IHC. The series studied included primary lung 
carcinomas of patients without a history of cancer (n = 175), 
primary lung carcinomas of patients in whom another, unre-
lated primary cancer had been diagnosed in the past (second 
primary LC, n = 36), and carcinomas with primary presenta-
tion in the lungs of which the origin of the carcinomas (i.e., 
primary or metastasis) was equivocal at the time of diagno-
sis (TOD) (n = 12). The GP5+/6+ PCR/p16INK4a IHC double-
positive tumor specimens were subjected to genotyping of 
GP5+/6+ PCR products, HPVE7 transcript analysis, loss 
of heterozygosity (LOH), and array comparative genomic 
hybridization (array CGH) analysis to understand the clinical 
meaning of an active hrHPV infection in the lungs.
MATERIALS AND METHODS
Tissue Specimens
Archival tumor tissue specimens from 223 patients (145 
men, 78 women, median age 65 years, range 27–87 years), 
who presented with cancer in the lungs, were retrieved from 
the archive of the Department of Pathology, VU University 
Medical Center, Amsterdam, The Netherlands (Table 1). 
According to the clinical and pathology records, the series 
included 211 patients with primary lung carcinomas, and 12 
patients with carcinomas with primary presentation in the 
lungs of which the origin of the carcinomas was equivocal 
at the TOD and could represent tumors with a primary or 
secondary manifestation in the lungs. The primary lung car-
cinomas were from patients without a history of cancer (n 
= 175) or patients in whom another, unrelated primary can-
cer had been diagnosed in the past (second primary LC; n = 
36). Information was obtained from the Dutch nationwide 
network and registry of histo- and cytopathology (PALGA, 
Utrecht, The Netherlands).23 Collection, storage, and use of 
archival tissue and patient data were performed in compliance 
with the Code for Proper Secondary Use of Human Tissue in 
The Netherlands (http://www.fmwv.nl and www.federa.org). 
This study followed the ethical guidelines of the Institutional 
Review Board and was approved by the Institutional Review 
Board.
Tissue Processing and Isolation of Nucleic Acids
Tissue sections were prepared according to the sand-
wich method, in which the outer sections were stained by hae-
matoxylin and eosin for histological analysis, and in-between 
sections were used for p16INK4a immunostaining (3 µm) and 
nucleic acid isolation (10 µm). After the deparaffinization of 
respective tissue sections, DNA was isolated using Proteinase 
K (Roche Diagnostics, Almere, The Netherlands) digestion 
(overnight at 52°C) followed by phenol-chloroform extrac-
tion, as described previously.24 Total RNA was extracted using 
TRIzol reagent (Life Technologies, Breda, The Netherlands) 
according to manufacturer’s instructions. Several precautions 
were taken to prevent false-positive test results. The micro-
tome was cleaned between sectioning of separate specimens, 
and a new microtome blade was installed for each specimen 
to avoid sample cross-contamination. Subsequent steps, such 
as sample preparation and PCR amplification were performed 
in strictly separated rooms, and distilled water samples were 
included as negative PCR controls. None of the controls was 
positive for any of the HPV assays.
HPV DNA Detection and Genotyping
DNA isolates were subjected to GP5+/6+ PCR with an 
enzyme immunoassay read-out using a probe cocktail of 14 
high-risk HPV types (i.e., HPV 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, and 68) and 23 low-risk HPV types (i.e., 
HPV 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70, 71, 
72, 73, 81, 82/mm4, 82/is39, 83, 84, and cp6108) essentially 
as described before.25,26 Subsequent genotyping of enzyme 
immunoassay–positive samples was performed as described 
previously.26 Beta-globin PCR was performed on each DNA 
isolate as a quality control.
Detection of HPVE7 mRNA by Reverse-
Transcriptase–PCR
Detection of type-specific HPVE7 mRNA was 
performed essentially as described before.27 Amplicon sizes 
were 109, 77, and 103bp for HPV16, HPV18, and HPV33 
(primers available on request), respectively. RQ-1 DNAse 
(Promega, Leiden, The Netherlands) treatment was applied to 
reduce the signal from contaminating genomic DNA. Besides 
DNAse treatment, reverse-transcriptase (RT)–reactions were 
also performed without RT added to confirm absence of 
residual DNA. RT–PCR was performed on each RNA isolate 
with primers specific for the housekeeping gene U1 small 
nuclear ribonucleoprotein–specific A protein (snRNP U1A), 
as a measure of quality control.27 As a positive control, plasmid 
DNA of the respective HPV type was used in the PCR assay. 
All PCR products were visualized by gel-electrophoresis, 
using 2% agarose gel.
IHC Staining of p16INK4A
IHC was carried out using a mouse monoclonal antibody 
against p16INK4A (clone 16P04 [JC2]; Neomarkers, Fremont, 
CA) on a fully automated BOND-MAX (Leica Microsystems 
GmbH, Wetzlar, Germany) platform, using the Bond Polymer 
Refine Detection system (Vision BioSystems, Newcastle, 
United Kingdom). The sections were pretreated with Bond 
Epitope Retrieval Solution 2 (pH 9.0) (Vision BioSystems) for 
20 minutes at 99°C. As a negative control, a mouse monoclonal 
antibody against Rat oxytocin-related neurophysin was used. 
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All slides were examined by an expert pathologist (EB) for 
the presence of p16INK4A-positive staining. Moderate to strong 
diffuse nuclear and/or cytoplasmic immunoreactivity in more 
than 70% of the carcinoma tissue was considered as p16INK4A-
positive, whereas tissue with only faintly diffuse or none to little 
(≤70%) reactivity was considered to be p16INK4A -negative.28
LOH Analysis
Twelve microsatellite markers were used to assess 
allelic loss on chromosome arms 3p, 9p, 11q, and 17p: 
D3S1766, D3S1029, D3S1293, D9S171, D9S162, D9S157, 
D11S1883, D11S1369, D11S2002, CHRNB1, TP53, and 
D17S1866. Multiplex PCR analysis was performed on 50 ng 
of DNA, using sets of both labeled (FAM, HEX, NED) and 
unlabeled primers, to amplify the microsatellite markers, 
essentially as described previously.29 The ABI 3130 Genetic 
Analyzer (Applied BioSystems BV, Nieuwerkerk a/d IJssel, 
The Netherlands) was used to separate the labeled PCR prod-
ucts and measure the signal intensities, as described previ-
ously.29 Allelic loss was assigned if the signal intensity of one 
of the two alleles decreased by 50% or more, compared with 
normal reference DNA isolated from non-neoplastic tissue of 
the same patient.
Array CGH
For array CGH purposes, genomic DNA was isolated 
from FFPE tumor tissue specimens, using the column-based 
QIAamp DNA micro kit (Qiagen, Westburg, Leusden, The 
Netherlands) according to manufacturer’s protocol. The DNA 
isolation procedure was preceded by an overnight incubation 
(37°C) of the deparaffinized tissue samples with sodium 
thiocyanate (1 M) to reduce the number of formalin-induced 
DNA cross-links. Accordingly, normal mucosal DNA was 
isolated from FFPE biopsies obtained from 10 patients with 
nonmalignant respiratory disease to be used as a pooled 
reference sample. Tumor and reference DNA (500 ng) were 
labeled with either Cyanine 3-dUTP (Cy3) or Cyanine 
5-dUTP (Cy5) nucleotide mixtures, using the CGH labeling 
kit for oligo arrays (Enzo Life Sciences, Farmingdale, 
NY). Sample hybridizations were performed using the 
Agilent SurePrint G3 human CGH array 4 × 180K platform 
containing 180,880 in situ synthesized oligonucleotides 
evenly distributed over the genome (spacing of approximately 
17 kb), and 4548 additional unique oligonucleotides, covering 
238 of the Cancer Census genes (Agilent Technologies, Santa 
Clara, CA). In brief, labeled samples were combined in a 110 
μl mixture containing 39 μl of Cy3/Cy5 DNA mixture, 5 μg 
Cot-1 DNA (Invitrogen, Breda, The Netherlands), 10× Oligo 
aCGH blocking agent, and 2× Hi-RPM hybridization buffer 
(both obtained from Agilent Technologies). After incubation 
steps at 95°C for 3 minutes and 37°C for 30 minutes, the 
mixture was applied to the array-slide for hybridization (24 
hours at 65°C). Array image acquisition and image analysis 
was done using an Agilent G2505B microarray scanner and 
feature extraction software v10.7.3.1 (Agilent Technologies), 
respectively. Log
2
 ratios (test/reference signal intensities) were 
calculated for each spot and normalized against the median of 
the ratios of all autosomes. Raw data are available through 
the Gene Expression Omnibus, accession number GSE40777.
Array CGH Data and Statistical Analysis
Array CGH data analysis was performed using the 
statistical programming package R (v2.10.1). To overcome 
potential wave bias because of differences in GC-content of 
the different chromosomal regions, a smoothing algorithm was 
applied on our data set.30 The CGH call algorithm was used for 
recovering the segmental structure of normalized copy num-
ber profiles and defining the discrete copy number states of 
all chromosomal regions.31 To distinguish somatic focal copy 
number aberrations from germline copy number variations, all 
focal aberrations (<3 Mb) that were identified using the called 
copy number data were compared with a database of known 
TABLE 1.  Characteristics of Study Population
Tissue Specimens Patient Group Histology n Sex (M / F) Median Age (Yrs, Range) hrHPV–Positive n (%)
Primary LC No history of cancer AdCa 82 41 / 41 63 (35–84) 0 (0)
SCC 68 60 / 8 70 (47–87) 0 (0)
LCC 16 11 / 5 65 (47–74) 0 (0)
NOS 9 4 / 5 66 (52–70) 0 (0)
Unrelated cancer in the past AdCa 16 10 / 6 67 (48–80) 0 (0)
SCC 17 11 / 6 62 (27–77) 0 (0)
LCC 3 0 / 3 63 (61–74) 0 (0)
NOS — — — —
Total 211 137 / 74 65 (27–87) 0 (0)
Equivocal LC Cancer in the past AdCa 3 2 / 1 66 (58–70) 1 (12.5)
SCC 8 5 / 3 63 (39–74) 2 (66.7)
LCC 1 1 / 0 66 (66–66) 0 (0)
NOS — — — —
Total 12 8 / 4 64 (39–74) 3 (25)
F, female; hrHPV, high-risk human papillomavirus; M, male; AdCa, adenocarcinoma; SCC, squamous cell carcinoma; LC, lung cancer; LCC, large cell carcinoma; NOS, non–
small-cell lung carcinoma not otherwise specified.
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copy number variations in the healthy population (database 
of genomic variants). To evaluate tumor clonality or indepen-
dency between tumor pairs, the copy number profiles of two 
tumors were compared using two measures of similarity: the 
likelihood ratio (LR) using R package Clonality,32,33 and the 
Pearson’s correlation coefficient on segmented data, using R.
RESULTS
Prevalence of hrHPV
All primary lung carcinomas were hrHPV-negative 
(211 of 211, 100%) (Table 1). Among the 12 carcinomas with 
equivocal origin at TOD (i.e., primary presentation of cancer 
in the lungs that may represent either second primary cancer 
or metastatic disease), three hrHPV–positive cancers (3 of 12, 
25%) were identified. The hrHPV–positive specimens com-
prised: a p16INK4A immunopositive squamous cell carcinoma 
(SCC) with HPV16 in a woman who had a history of cervical 
cancer (case 1); a p16INK4A-immunopositive adenocarcinoma 
(AdCa) with HPV18 in a woman who had a history of cervi-
cal cancer (case 2), and a p16INK4A immunopositive SCC with 
HPV33 in a man who had a history of tonsillar cancer (case 3; 
Table 2, Fig. 1). In addition, one lung SCC (case 4) was found 
positive for low-risk HPV type 11 in a patient with a history of 
juvenile laryngeal papillomatosis from 9 years of age onward. 
This tumor was p16INK4A immunonegative.
Assessment of Clonal Relationship
Further molecular studies were performed to assess the 
likelihood of a clonal relationship between tumor pairs. For 
these analyses tissue material of the carcinomas that were pre-
viously diagnosed in cases 1 and 3 (i.e., cervical carcinoma 
and tonsillar carcinoma, respectively) were available. HPV 
status, HPV genotype, and E7 viral oncogene expression 
showed concordant results with their respective lung carci-
nomas (Table 2). In addition, the pattern of p16INK4A immu-
nostaining and histomorphology were identical in tumor pairs 
(Fig. 1). Microsatellite analysis at chromosomal regions 3p, 
9p, 11q, and 17p demonstrated similar patterns of allelic (im)
balance between tumor pairs in both cases. In case 1, eight of 
the 12 markers were informative and revealed six concordant 
loci showing retention of heterozygosity, one concordant LOH 
at chromosome 9p (D9S157), and one locus (D3S1029) with 
acquired LOH in the lung tumor. In case 3, 10 of the 12 markers 
were informative and all showed concordant retention of het-
erozygosity between both tumors. DNA copy number profiles 
of respective tumor pairs were generated and vertically aligned 
according to genomic position, using array CGH analysis, as 
shown in Figure 2 for both cases. Genomic profiles of tumor 
pairs demonstrated a highly similar appearance (case 1; 40.6 
versus 31.6% aberrant genomic features; case 3; 24.2 versus 
23.8% aberrant genomic features). The two tumor profiles of 
case 1 revealed identical copy number gains at chromosomes 
3q and 9p, and identical copy number loss at 19p (Fig. 2A). In 
addition, identical focal aberrations were observed at chro-
mosome arms 4p (gain of 4p16.3) and 9p (gain of 9p22.3–
p22.1). Accordingly, tumor profiles of case 3 demonstrated 
identical chromosomal aberrations at chromosomes 3p and 
20p, supplemented with identical focal aberrations at chro-
mosome arms 9p (loss of 9p23) and 14q (loss of 14q21.2) 
(Fig. 2B). The degree of correlation between chromosomal 
segmentation patterns in both cases was marked (Pearson’s 
R = 0.68 and 0.39, respectively). The DNA copy number pro-
files from the analyzed tumor pairs were compared with a cal-
culated reference histogram originating from selected pairs 
of independent tumors, 32,33 and revealed a clonal relationship 
between paired tumors in both cases (i.e., case 1: LR = 8.7, 
and case 3: LR = 1.29).
DISCUSSION
In the present study, no support was found for an 
attribution of an hrHPV infection to the development of 
primary LC in a large series of primary LC specimens from 
a Dutch population. We provided molecular evidence that 
hrHPV presence, in fact, signified pulmonary metastasis 
from a primary hrHPV-associated cancer source elsewhere 
in the body. Our findings imply that one should be aware of 
metastatic disease in case of an hrHPV–positive cancer with 
primary presentation in the lungs.
On the basis of our results, the prevalence of hrHPV in 
primary LC is essentially 0%, which is in line with previous 
findings of Western population–based studies.15,34,35 The proof 
of pulmonary metastatic disease comprises an important clini-
cal aspect. The lungs are the most frequent site of metastatic 
spreading in extrapulmonary solid malignancy (i.e., 20%–54% 
of all cases),36 and the differentiation between second primary 
cancer or metastatic disease often poses a problem in case of 
patients presenting with cancer in the lungs. Whether the pres-
ence of pulmonary metastasis of an hrHPV-associated cancer 
generally accounts for the detection of hrHPV in LC tissue, or 
whether geographical differences exist, warrants further study, 
including patient history and molecular clonality analysis.
TABLE 2.  Overview of hrHPV–Positive Cancer Cases
Lung Carcinoma Previous Cancer
Patient ID (sex, age) Histo type HPV 
type
HPVE7 
mRNA
p16INK4A expression Organ, histo type TODa HPV 
type
HPVE7 
mRNA
p16INK4A expression
Case 1 (F, 52) SCC 16 + + Cervix, SCC 30 16 + +
Case 2 (F, 57) AdCa 18 + + Cervix, AdCa 12 nd nd nd
Case 3 (M, 62) SCC 33 + + Tonsil, SCC 53 33 + +
aTOD reported in months before the diagnosis of lung cancer.
AdCa, adenocarcinoma; F, female; M, male; nd, not done (i.e., no tissue material available for analysis); SCC, squamous cell carcinoma; hrHPV, high-risk human papillomavirus; 
TOD, time of diagnosis.
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Whereas Asian studies have reported on an association 
between HPV, lung AdCa and endothelial growth factor recep-
tor (EGFR) mutation,37,38 the current study found no evidence 
for hrHPV in primary lung AdCas, nor primary lung squa-
mous cell carcinomas. In our series, 11 EGFR-mutant primary 
lung AdCas (i.e., 7 cases with EGFR exon 19 deletion and 4 
cases with EGFR exon 21 point mutation p.L858R; data not 
shown) were represented, which were all hrHPV-negative. The 
present study in a Dutch population suggests no association 
between hrHPV and EGFR mutations. The low viral loads 
found in the Asian studies37,38 makes it difficult to determine 
the etiological significance of their findings.
Our findings of pulmonary metastatic disease are in 
line with those of case studies reporting on the occurrence 
of hrHPV–positive pulmonary metastases of cervical 
cancer, head-and–neck squamous cell carcinoma, and penile 
cancer.39–41 On the basis of the combination of morphology, 
HPV typing, and tumor genetics, this study provides strong 
evidence for a clonal relationship between tumors, making a 
primary LC highly unlikely. Our data underscore the value of 
p16INK4a IHC together with GP5+/6+ PCR on FFPE specimens 
to measure a biologically relevant association between hrHPV 
infection and cancer.12,22 The low levels of allelic loss in the 
LCs further support the presence of a transcriptionally active 
hrHPV infection.42 Our findings underline the valuable role 
of HPV genotyping, LOH analysis, and array CGH analysis 
as diagnostic tools to discriminate primary from metastatic 
LC.39,40,43,44
In this study, one patient was detected with low-risk 
HPV11 in the LC tissue. The patient history showed laryngeal 
papillomatosis from an early age. HPV genotyping of the 
papillomatosis revealed HPV11 (data not shown), suggesting 
a direct association. Despite the fact that HPV11 is generally 
recognized as non-oncogenic, malignant transformation has 
been reported for individuals with juvenile-onset recurrent 
respiratory papillomatosis (RRP), particularly cancers 
arising in the upper and lower respiratory tract.45–47 Whether 
malignant transformation in RRP is due to viral integration of 
HPV1148 or resulting from an alternative etiological factor, for 
example, p53 mutation47,49 or hrHPV coinfection,50 remains 
FIGURE 1.  p16INK4A Expression patterns 
in tumor pairs. Immunohistochemical 
staining patterns for p16INK4A are shown 
for (A) paired tumors of case 1, (B) LC 
of case 2, and (C) paired tumors of case 
3. Photograps were taken using a 100× 
magnification. AdCa, adenocarcinoma; 
LC, lung cancer; SCC, squamous cell 
carcinoma.
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inconclusive with only few reported studies. The latter, 
however, seems unlikely, given the lack of p16INK4A expression 
and non-detection of hrHPV DNA in our LC case. A recent 
article by Yuan et al.51 reported on a mutant HPV11 genome 
with duplication of the promoter and oncogene regions in lung 
tumor tissue of a patient with RRP, and speculated that the 
duplication of the viral regions was associated with the clinical 
aggressiveness of the tumor in the patient. Rearrangements of 
HPV11 genomes have originally been reported in a metastasis 
of LC in a patient with juvenile-onset HPV 11–positive 
laryngotracheobronchial papillomatosis.52 Yuan et al.51 also 
reported on vorinostat for the treatment of the HPV11-related 
LC with stabilized tumor size with a durable effect at 15 
months.51 These findings hold promise for the treatment of 
HPV11-related LCs.
In summary, our results provide strong evidence for 
hrHPV–positive lung carcinoma being, in fact, a pulmonary 
metastasis from an hrHPV-associated primary carcinoma 
FIGURE 2.  Genomic profiles support a common clonal origin in tumor pairs. DNA copy number aberrations for tumor pairs 
originating from (A) case 1 and (B) case 3 as detected by array CGH are shown. Genomic profiles were aligned according to 
chromosomal position (x axis) and display log2 tumor to normal ratios (y axis). Both individual array measurements (180K in 
total, represented by gray dots) and respective segmented values (black lines) are indicated. Gain and loss are positive and 
negative log2 ratio, respectively.
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originating elsewhere in the body. Our data, together with the 
findings of previous studies,15,34,35 do not support a role for 
hrHPV infection attributable to primary lung carcinoma in 
Western populations.
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